Novo Nordisk's diabetes pill Rybelsus has shown significant cardiovascular benefits, reducing the risk of heart-related issues by 14%. This could offer a new, convenient treatment option for many patients.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
